Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Vertex

The World's First CRISPR Gene Therapy Just Got Approved for Children as Young as 2 with Sickle Cell Disease

The FDA on July 1, 2026, expanded Casgevy CRISPR gene therapy to children as young as 2 with sickle cell disease. Here is what families need to know about eligibility and access.

Medical Daily

FDA Expands CRISPR Gene Therapy Casgevy to Children as Young as 2 with Sickle Cell Disease

FDA approved Casgevy CRISPR gene therapy for children as young as 2 with sickle cell disease on July 1, 2026. Here's what families need to know about this milestone.

Medical Daily

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

IT services growth likely to stay soft in near term as clients delay discretionary spends: Equirus

India's major IT firms anticipate a subdued first quarter, with growth expected to pick up only when clients shift from cost-cutting to AI-driven transformations. Enterprises remain cautious with spending due to global uncertainties, funding AI through existing savings. While currency tailwinds and better margins are positive, revenue growth is likely…

The Economic Times

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

MarketBeat

Trinasolar and Ecohope Solar Sign 600MW MoU to Distribute Latest Vertex G3 Modules Across Southeast Asia, the Middle East and Africa

SHANGHAI, June 10, 2026 /PRNewswire/ -- Trinasolar, a global leader in smart PV and energy storage solutions, has signed a Memorandum of Understanding (MoU) with Ecohope Solar, a global PV and ESS solutions provider with offices in China, Thailand and the UAE. The MoU was signed at SNEC PV Power…

AAP

This £13k Ortofon MC Vertex is the firm's "most advanced moving coil cartridge" ever – and is joined by a new MC X model

Promises more accurate groove tracing and signal generation

What Hi-Fi?

Read news from The Economist, FT, and more,
with one subscription

Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host

MarketBeat

MaxCyte Q1 Earnings Call Highlights

MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the declin

MarketBeat

As GitLab Expands Its Google Cloud Deal, Should You Buy GTLB Stock?

GTLB stock popped on an extended deal with Google Cloud, which is integrating with its GitLab Duo Agent Platform.

Barchart

What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report

Vertex Pharmaceuticals is set to report its first-quarter results next month, and analysts are expecting high single-digit growth in earnings.

Barchart

Is Vertex Stock Outperforming the Dow?

Despite underperforming the Dow Jones Industrial Average over the past year, Vertex continues to earn moderate bullish support from analysts.

Barchart

Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Guitar World

“Brings ideas to life that I’ve been refining for over 17 years as a professional rig builder”: Gator teams up with Vertex Effects for a one-stop “unified pedalboard system” –complete with ’boards, bags and fasteners

Made with durable material, in three different sizes with and without risers, direct collaboration leaves no stone unturned in the quest for the ultimate pedalboard

Barchart

Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report

Vertex Pharmaceuticals is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings growth

The Guardian - UK

‘We were sitting with our calculator saying “we can afford that!”’ Joy for families as cystic fibrosis drug prices fall within reach

The cost of medication was too high for thousands of CF sufferers around the world. Now a Bangladeshi company is making a generic version that will change lives

Benzinga

Vertex's Gene Therapy Works In Children With Blood Disorders

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Saturday presented data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in patients aged 5 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?

Vertex Pharmaceuticals has underperformed the broader Nasdaq index over the past year. However, Wall Street analysts remain moderately optimistic about its prospects.

Barchart

Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings

Vertex Pharmaceuticals’ stock has trailed behind the broader market, but analysts are still taking a moderately bullish stance about its prospects.

Benzinga

Vertex CEO David DeStefano Steps Down After 26 Years

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025.

Barchart

Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report

Vertex Pharmaceuticals is set to post its third-quarter results next month, and analysts project a single-digit earnings drop.

Kiplinger

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

TechRadar

Building AI-ready finance teams, not just AI tools

AI is revolutionizing finance by empowering tax teams with technology, skills, and a culture shift.

Barchart

Do Wall Street Analysts Like Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has significantly underperformed the broader market over the past year, yet analysts remain optimistic about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals

65 stories

Vertex Pharmaceuticals Incorporated

65 stories

Vertex Pharmaceuticals

63 stories

Gator

46 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.